0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LILRB2

LILRB2

Brief Information

Name:Leukocyte immunoglobulin-like receptor subfamily B member 2
Target Synonym:Myeloid Inhibitory Receptor 10,CD85d Antigen,ILT4,LIR2,CD85d,LIR-2,Leukocyte immunoglobulin-like receptor 2,CD85 antigen-like family member D,Immunoglobulin-like transcript 4,ILT-4,Monocyte/macrophage immunoglobulin-like receptor 10,MIR-10,CD_antigen: CD8
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

LI2-H5220-ELISA
Human LILRB2, His TagHuman LILRB2, His Tag (Cat. No. LI2-H5220) ELISA bioactivity

Immobilized Human LILRB2, His Tag (Cat. No. LI2-H5220) at 1 μg/mL (100 μL/well) can bind Anti-LILRB2 Antibody, Human IgG1 with a linear range of 0.5-4 ng/mL (QC tested).

CDD-H5259-ELISA
Human LILRB2, Fc TagHuman LILRB2, Fc Tag (Cat. No. CDD-H5259) ELISA bioactivity

Immobilized Human LILRB2, Fc Tag (Cat. No. CDD-H5259) at 1 μg/mL (100 μL/well) can bind Anti-LILRB2 Antibody, Human IgG1 with a linear range of 1-2 ng/mL (QC tested).

Synonym Name

LILRB2,ILT4,LIR2,MIR10,CD85d

Background

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JTX-8064 JTX-8064 Phase 1 Clinical Jounce Therapeutics Neoplasms Details
NGM-707 Phase 2 Clinical Merck & Co, Ngm Biopharmaceuticals Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Glioblastoma; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
MK-4830 MK-4830 Phase 2 Clinical Merck Sharp & Dohme Corp Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop